BR0012446A - Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma - Google Patents

Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma

Info

Publication number
BR0012446A
BR0012446A BR0012446-0A BR0012446A BR0012446A BR 0012446 A BR0012446 A BR 0012446A BR 0012446 A BR0012446 A BR 0012446A BR 0012446 A BR0012446 A BR 0012446A
Authority
BR
Brazil
Prior art keywords
tarp
protein
cells
alternative reading
reading network
Prior art date
Application number
BR0012446-0A
Other languages
English (en)
Inventor
Ira Pastan
Magnus Essand
Byungkook Lee
George Vasmatzis
Curt Wolfgang
Ulrich Brinkmann
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR0012446A publication Critical patent/BR0012446A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção: "PROTEìNA DA REDE DE LEITURA ALTERNATIVA DO RECEPTOR~ Y~ DE CéLULAS T E USO DA MESMA". A presente invenção proporciona ácidos nucleicos contendo seq³ências de um transcrito de TCRY de células epiteliais de próstata e muitas células de câncer de mama e uma Proteína da Rede de Leitura Alternativa do receptor gama de células T ("TARP") expressa a partir da tradução dessas seq³ências. Vacinas feitas da TARP são úteis na estimulação de respostas imunes à células nas quais a proteína é expressa, incluindo células de câncer de próstata e células de muitos canceres de mama. A invenção também proporciona métodos para diagnóstico da presença de câncer de próstata e canceres de mama que expressam a TARP, bem como métodos de administração da TARP e ácidos nucleicos que codificam a TARP a indivíduos.
BR0012446-0A 1999-07-13 2000-07-12 Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma BR0012446A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14356099P 1999-07-13 1999-07-13
US15747199P 1999-10-01 1999-10-01
PCT/US2000/019039 WO2001004309A1 (en) 1999-07-13 2000-07-12 T-CELL RECEPTOR η ALTERNATE READING FRAME PROTEIN, (TARP) AND USES THEREOF

Publications (1)

Publication Number Publication Date
BR0012446A true BR0012446A (pt) 2002-04-02

Family

ID=26841157

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012446-0A BR0012446A (pt) 1999-07-13 2000-07-12 Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma

Country Status (15)

Country Link
US (1) US7052703B1 (pt)
EP (1) EP1200585A1 (pt)
JP (1) JP2004512809A (pt)
KR (1) KR20020026530A (pt)
CN (1) CN1378594A (pt)
AU (1) AU781925B2 (pt)
BR (1) BR0012446A (pt)
CA (1) CA2379345A1 (pt)
HK (1) HK1049499A1 (pt)
IL (1) IL147507A0 (pt)
MX (1) MXPA02000560A (pt)
NO (1) NO20020110L (pt)
PL (1) PL354186A1 (pt)
RU (1) RU2002103722A (pt)
WO (1) WO2001004309A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354186A1 (en) * 1999-07-13 2003-12-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, asTHE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTH AND HUMAN SERVICES T-cell receptor gamma alternate reading frame protein, (tarp) and uses thereof
WO2004064868A1 (en) * 2003-01-22 2004-08-05 Magnus Essand Tarp promoter and uses thereof
US7541035B2 (en) 2003-06-05 2009-06-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
DK2918598T3 (en) * 2007-02-28 2019-04-29 The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services Brachyury polypeptides and methods of use
EP2895191B1 (en) 2012-09-14 2019-06-05 The U.S.A. as represented by the Secretary, Department of Health and Human Services Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
LT4095130T (lt) 2013-10-18 2024-04-25 Novartis Ag Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti
WO2015089469A1 (en) 2013-12-13 2015-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multi-epitope tarp peptide vaccine and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354186A1 (en) * 1999-07-13 2003-12-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, asTHE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES HEALTH AND HUMAN SERVICES T-cell receptor gamma alternate reading frame protein, (tarp) and uses thereof
WO2003009814A2 (en) * 2001-07-25 2003-02-06 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Also Published As

Publication number Publication date
AU6093000A (en) 2001-01-30
US7052703B1 (en) 2006-05-30
AU781925B2 (en) 2005-06-23
JP2004512809A (ja) 2004-04-30
WO2001004309A1 (en) 2001-01-18
RU2002103722A (ru) 2003-08-27
CA2379345A1 (en) 2001-01-18
NO20020110L (no) 2002-03-12
CN1378594A (zh) 2002-11-06
EP1200585A1 (en) 2002-05-02
NO20020110D0 (no) 2002-01-09
PL354186A1 (en) 2003-12-29
MXPA02000560A (es) 2003-10-14
HK1049499A1 (zh) 2003-05-16
KR20020026530A (ko) 2002-04-10
IL147507A0 (en) 2002-08-14

Similar Documents

Publication Publication Date Title
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
AR032743A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
CY1105212T1 (el) Αντισωματα αντι-april και κυτταρα υβριδωματος
HUP0002760A2 (hu) CCK-B/gasztrin-receptor elleni ellenanyagok termelődését kiváltó immunogén készítmények, és alkalmazásuk tumorok kezelésére
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR0012446A (pt) Proteìna da rede de leitura alternativa do receptory de células t e uso da mesma
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
TR200101702T2 (tr) Mammaglobin, göğse özgü salgılanan bir göğüs kanseri proteini.
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
DE50013990D1 (de) Einem Peptid aus Antigen MUC-1 entsprechende DNS zur Auslösung einer Immunreaktion gegen Tumorzellen
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
ATE287900T1 (de) Das antigen ha-1
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
BR0009573A (pt) Composições e métodos para o tratamento e diagnose do câncer de mama
DK1993595T3 (da) Tumorvaccine omfattende allogene eller xenogene tumorceller
AR029547A1 (es) Composiciones y metodos para la terapia y el diagnostico de cancer de pulmon
AR023794A1 (es) Antigeno asociado con tumores
DE60216045D1 (de) Krebsdiagnoseverfahren
ATE259655T1 (de) Aus ganzen zellen bestehender krebs-impfstoff, enthaltend ko-kultivierte maligne und nicht- maligne zellen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.